LUPIN LTD
Add to watch list to get report alerts
BSE Code:
500257
NSE Code:
LUPIN
Business Profile
Business Profile
Lupin came into existence following the amalgamation of Lupin laboratories with Lupin Chemicals. Its activities include pharmaceuticals, bulk drugs and formulations, fermentation, bio-technology, natural products and agro chemicals.
Its Lupin division offers solutions in the respiratory segment that covers anti-TB, anti-asthma (inhalation segment), anti-infectives, anti-allergies and supportive therapy products. The top six products in the API basket viz., cephalexin and cefaclor (anti-lnfectives), 7ADCA and 7ACCA (cephalosporin intermediates), ethambutol and rifampicin (anti-TB) cover nearly 80% of API sales to the semi regulated markets. Lisinopril (cardiovascular) forms the core API sales to the regulated markets. The biggest brand of the company is R-Cinex.
The Lupin division dominates the anti-TB segment with a market share of 45%. Its finished dosages business has outperformed the market growth rate by nearly two-and-half times. The company filed for 14 ANDAs and 15 DMFs and now has four molecules in clinical trials. It raised its R&D expenditure to 7.2% of net sales in 2004-2005 to create commercially viable intellectual property for the company. Its AKT-4 now occupies a 7.5% market share in the 4-drug combipack segment.
Lupin has set its focus on broad-spectrum anti-bacterials, anti-asthma and diabetic research. The company has plans to enter new non-conventional route of drug administration. Synthesis of drugs involving complex chemistry/technology has been identified for process development research. New herbal leads for new indications have been identified for further development. It also plans to tap emerging opportunities for licensing-out products.
Financials
The company disclosed a substantial drop in standalone net profit for the quarter ended December 2008. During the quarter, the profit of the company declined 48.24% to Rs 881.40 million from Rs 1,702.80 million in the same quarter last year. Net sales for the quarter rose 19.87% to Rs 7,288.60 million, while total income for the quarter fell marginally 2.40% to Rs 7,291.10 million, when compared with the prior year period. It posted earnings of Rs 10.66 a share during the quarter, registering 48.63% decline over prior year period.
Recent Developments
27-MAR-09
The company completed the acquisition of a majority stake in Multicare (MC) Pharmaceuticals, in Philippines.
16-JAN-09
Company`s US subsidiary, Lupin Pharmaceuticals, received final Abbreviated New Drug Application (ANDA) approval for Levetiracctam tablet 250 mg, 500 mg, 750 mg and 1000 mg from the US Food and Drug Administration (USFDA).
17-DEC-08
The company announced that it has settled all ongoing Hatch-Waxman litigation relating to Desloratadine tablets, the generic version of Schering-Plough`s `Clarinex` tablets.
10-NOV-08
Indian pharmaceutical major the company has received an approval from Drug Controller General of India (DCGI) to launch India`s first selective and specific sinus node If channel inhibitor; IVABRAD (Ivabradine) which is now available in 5 mg and 7.5 mg tablets. IVABRAD comes from Pinnacle, Lupin`s marketing division for specialty drugs in India.